Second collaboration builds on rapid progress of AI-designed KAT6 inhibitor licensed in 2024 Agreement includes $20 million upfront payment with potential total value exceeding $550 million plus tiered royalties New preclinical asset demonstrates broad anti-tumor activity across multiple solid tumor types Less than a year after their first collaboration, pharmaceutical giant Menarini Group and AI-driven…
CEO: Insilico on how AI can ‘imagine the perfect molecules’ for drug targets
Insilico Medicine, an AI-based biotech startup, announced details of their first AI-designed drug candidate to enter human clinical trials. INS018_055 is an experimental treatment for idiopathic pulmonary fibrosis, a rare lung disease. Through their Insilico AI-driven drug discovery platform, they discovered and designed INS018_055 in just 30 months, significantly faster than the industry average. Phase…